Literature DB >> 15696851

Non-alcoholic fatty liver disease: a brief review.

B van Hoek1.   

Abstract

The term 'non-alcoholic fatty liver disease' (NAFLD) includes cases with steatosis alone and those with non-alcoholic steatohepatitis (NASH). Usually there are no signs or symptoms, sometimes fatigue or pain, and apart from hepatomegaly the condition is revealed by abnormal liver biochemistry or by abdominal ultrasound. Most cases are associated with overweight or diabetes. Liver enzymes are usually elevated, especially GGT, ASAT and ALAT. Other conditions, including alcohol abuse and autoimmune hepatitis, have to be excluded. The diagnosis of steatosis can be made with ultrasound or CT scan. A liver biopsy is often needed to exclude other disease and to assess inflammation and fibrosis. Cirrhosis can develop. NAFLD is usually caused by two 'hits': the 'first hit' is peripheral insulin resistance, causing steatosis. The 'second hit' is caused by reactive oxygen species, inducing vicious cycles leading to inflammation. Weight loss, metformin or thiazolidinediones can improve NAFLD by increasing insulin sensitivity. Radical scavengers such as vitamin E, betaine and perhaps also urodeoxycholic acid may improve the hepatitis component. Further studies on treatment are needed.

Entities:  

Mesh:

Year:  2004        PMID: 15696851     DOI: 10.1080/00855920410011013

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

Review 1.  Roles of liver innate immune cells in nonalcoholic fatty liver disease.

Authors:  Yu-Tao Zhan; Wei An
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

2.  Primary non-alcoholic fatty liver disease in hypertensive patients.

Authors:  Luminita Latea; Stefania Negrea; Sorana Bolboaca
Journal:  Australas Med J       Date:  2013-06-30

3.  Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease.

Authors:  Julia L Newton; Jessie Pairman; Katharine Wilton; David E J Jones; Christopher Day
Journal:  Clin Auton Res       Date:  2009-12       Impact factor: 4.435

4.  Effects of salvianolic acid B on liver mitochondria of rats with nonalcoholic steatohepatitis.

Authors:  Ying-Chun Wang; Wei-Zong Kong; Qing-Mei Jin; Juan Chen; Lei Dong
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

5.  Hepatic fat during fasting and refeeding by MRI fat quantification.

Authors:  Sreenath Narayan; Chris A Flask; Satish C Kalhan; David L Wilson
Journal:  J Magn Reson Imaging       Date:  2014-03-03       Impact factor: 4.813

6.  Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept.

Authors:  Gonca G Bural; Drew A Torigian; Anne Burke; Mohamed Houseni; Khaled Alkhawaldeh; Andrew Cucchiara; Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2009-10-06       Impact factor: 3.488

7.  Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease.

Authors:  Irene P Tzanetakou; Ilias P Doulamis; Laskarina-Maria Korou; George Agrogiannis; Ioannis S Vlachos; Alkisti Pantopoulou; Dimitri P Mikhailidis; Efstratios Patsouris; Ioannis Vlachos; Despina N Perrea
Journal:  Open Cardiovasc Med J       Date:  2012-08-10

8.  Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.

Authors:  A L Han
Journal:  BMC Endocr Disord       Date:  2021-05-01       Impact factor: 3.263

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.